ITMI932412A0 - Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce - Google Patents

Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce

Info

Publication number
ITMI932412A0
ITMI932412A0 ITMI932412A ITMI932412A ITMI932412A0 IT MI932412 A0 ITMI932412 A0 IT MI932412A0 IT MI932412 A ITMI932412 A IT MI932412A IT MI932412 A ITMI932412 A IT MI932412A IT MI932412 A0 ITMI932412 A0 IT MI932412A0
Authority
IT
Italy
Prior art keywords
blockers
alpha
treatment
premature ejaculation
ejaculation
Prior art date
Application number
ITMI932412A
Other languages
English (en)
Inventor
Giorgio Cavallini
Original Assignee
Giorgio Cavallini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giorgio Cavallini filed Critical Giorgio Cavallini
Priority to IT93MI002412A priority Critical patent/IT1264965B1/it
Publication of ITMI932412A0 publication Critical patent/ITMI932412A0/it
Priority to PCT/EP1994/003661 priority patent/WO1995013072A1/en
Priority to JP7513583A priority patent/JPH09504798A/ja
Priority to US08/624,603 priority patent/US5707999A/en
Priority to EP94931582A priority patent/EP0728000A1/en
Publication of ITMI932412A1 publication Critical patent/ITMI932412A1/it
Application granted granted Critical
Publication of IT1264965B1 publication Critical patent/IT1264965B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT93MI002412A 1993-11-12 1993-11-12 Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce IT1264965B1 (it)

Priority Applications (5)

Application Number Priority Date Filing Date Title
IT93MI002412A IT1264965B1 (it) 1993-11-12 1993-11-12 Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
PCT/EP1994/003661 WO1995013072A1 (en) 1993-11-12 1994-11-08 The use of alfuzosin or terazosin in the treatment of premature ejaculation
JP7513583A JPH09504798A (ja) 1993-11-12 1994-11-08 早発性射精の治療におけるアルフゾシンまたはテラゾシンの使用
US08/624,603 US5707999A (en) 1993-11-12 1994-11-08 Use of alfuzosin or terazosin in the treatment of premature ejaculation
EP94931582A EP0728000A1 (en) 1993-11-12 1994-11-08 The use of alfuzosin or terazosin in the treatment of premature ejaculation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT93MI002412A IT1264965B1 (it) 1993-11-12 1993-11-12 Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce

Publications (3)

Publication Number Publication Date
ITMI932412A0 true ITMI932412A0 (it) 1993-11-12
ITMI932412A1 ITMI932412A1 (it) 1995-05-12
IT1264965B1 IT1264965B1 (it) 1996-10-17

Family

ID=11367195

Family Applications (1)

Application Number Title Priority Date Filing Date
IT93MI002412A IT1264965B1 (it) 1993-11-12 1993-11-12 Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce

Country Status (5)

Country Link
US (1) US5707999A (it)
EP (1) EP0728000A1 (it)
JP (1) JPH09504798A (it)
IT (1) IT1264965B1 (it)
WO (1) WO1995013072A1 (it)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228864B1 (en) 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US5922341A (en) * 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
US6037360A (en) * 1997-10-28 2000-03-14 Vivus, Incorporated Administration of 5-HT3 receptor antagonists to treat premature ejaculation
EP1889614A3 (en) 1999-09-03 2010-09-22 APBI Holdings, LLC Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
CA2390903A1 (en) 1999-11-11 2001-05-17 Medicare Management Consultancy Limited Apparatus and method to assist in the diagnosis of premature ejaculation
US6495154B1 (en) 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
CN1289071C (zh) 2001-03-16 2006-12-13 Dmi生物科学公司 曲马朵物质在制备用于延缓男性射精的药物中的用途
US8575169B2 (en) * 2001-10-29 2013-11-05 Versi Group, Llc Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
US7683168B2 (en) * 2005-04-14 2010-03-23 Mount Cook Bio Sciences, Inc. Compositions of novel opioid compounds and method of use thereof
US8604082B2 (en) 2005-12-13 2013-12-10 Trinity Laboratories, Inc. Method to treat premature ejaculation in humans
US20080160081A1 (en) * 2006-12-11 2008-07-03 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making, and methods of use
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
US7767248B2 (en) 2007-02-02 2010-08-03 Overly Iii Harry J Soft chew confectionary with high fiber and sugar content and method for making same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399581A (en) * 1990-12-26 1995-03-21 Laragh; John H. Method and compositions for treatment of sexual impotence

Also Published As

Publication number Publication date
WO1995013072A1 (en) 1995-05-18
ITMI932412A1 (it) 1995-05-12
IT1264965B1 (it) 1996-10-17
EP0728000A1 (en) 1996-08-28
US5707999A (en) 1998-01-13
JPH09504798A (ja) 1997-05-13

Similar Documents

Publication Publication Date Title
BR9608758A (pt) Uso de ribavirina e interferom alfa para o tratamento de hepatite c
ITMI932412A0 (it) Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
IT8223892A0 (it) Composizione di antralina migliorata e suo uso nel trattamento di malattie della pelle.
IT8920413A0 (it) Procedimento per la preparazione di l alfa glicerilfosforilcolina e l alfa glicerilfosforiletanolammina.
ITMI912509A0 (it) Uso della nimesulide nel trattamento della cataratta
SE8902064D0 (sv) Rivningsbar sparkropp
KR950013377U (ko) 쑥뜸구
IT8025482A0 (it) Membrana modificata morfologicamente ed uso della stessa in procedimenti di elettrolisi.
PT804199E (pt) Uso de penciclovir para o tratamento de nevralgias pos-herpeticas
ITMI931673A0 (it) Uso della benzidamina nel trattamento di stati patologici causati dal tnf
KR930026025U (ko) 지압구를 겸한 손전등
ITMI941064A0 (it) Uso della s-benzoilossimetiltiamina nel trattamento del diabete
ITMI931800A0 (it) Uso della 4 -desossi-4-iododoxorubicina per il trattamento della alamiloidosi
ITTO920683A1 (it) Impiego di frammenti o/e di derivati della timosina alfa 1.
KR950010930U (ko) 쑥뜸구
ITMI940298A0 (it) Uso del ceruletide (takus) nel trattamento della psoriasi
ITMI921853A1 (it) Uso della n-acetil-cisteina nella prevenzione e nel trattamento della discinesia tardiva
ITMI931598A0 (it) Uso terapeutico della fosfocreatina
IT8219207A0 (it) Membrana modificata morfologicamente ed uso della stessa in procedimenti di elettrolisi.
IT1302920B1 (it) Uso della propoli nel trattamento della vitiligine e della psoriasi.
IT8735861V0 (it) Pulsantiera per telecomando dotatadi illuminazione dei tasti per l'osservazione e l'uso in assenza di il luminazione esterna
ITMI950773A0 (it) Uso della s-benzoilossimetiltiamina nel trattamento del diabete mellito
ITMI912511A1 (it) Uso di formulazioni liposomiali contenenti papaverina nel trattamento della impotenza maschile
ES1022407Y (es) Captadioptrico de uso personal.
IT8421807A1 (it) Composizione utile nel trattamento della diarrea

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19971127